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Background: Obesity is associated with increased adipose tissue and glucose intolerance. High-fat diets (HFDs) are
known to induce obesity and increase proinflammatory adipokines. The consumption of green tea may improve
the health of obese individuals because it contains a potent antioxidant that has effects on body weight, energy
expenditure and serum cholesterol concentrations.
Methods: We examined the effects of epigallocatechin-3-gallate (EGCG) (50 mg/kg body weight per day) or saline
after 30 or 60 days of treatment. Mice were distributed into four groups: 1) NS: normolipidic diet receiving saline; 2)
NE: normolipidic diet receiving EGCG; 3) HFS: high-fat diet receiving saline; 4) HFE: high-fat diet receiving EGCG.
Results: We observed that administration of a HFD plus EGCG treatment for 60 days reduced delta weight, the
relative weights of the mesenteric adipose tissue (MES), retroperitonial adipose tissue (RET), epididymal adipose
tissue (EPI), the sum of the adipose tissues (SAT), reduced triacylglycerol (TG) and improved both high-density
lipoprotein (HDL) cholesterol levels and the adiponectin/STA ratio when compared with HFS.
Conclusions: Our results suggest that the chronic administration of EGCG (60 days) promoted a significant
improvement in glucose tolerance, decreased adipose tissue deposits, weight mass, TG and HDL-C only when
associated with high-fat diet treatment.
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Obesity is characterised by excessive fat accumulation
and a resultant imbalance in energy intake and expend-
iture. Notably, HFD is the mainstream food habit of
modern society and is one of the major factors contrib-
uting to obesity [1]. The obese state is characterised by
low-grade systemic inflammation, primarily resulting from
increased adipocyte size and the recruitment of macro-
phages into the white adipose tissue (WAT) [2]. Adipose
tissue is an endocrine organ that releases protein factors,
known as adipokines which include hormones implicated
in energy balance (e.g. leptin and adiponectin), glucose
tolerance and insulin sensitivity (adiponectin and resistin)* Correspondence: mayaramoreno@hotmail.com
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unless otherwise stated.and classical cytokines (e.g. TNF-α, interleukin-6 and 10)
[3,4].
Several strategies have been adopted for treatment and
prevention of obesity, as well as for associated conditions,
such as insulin resistance, inflammation and hypertension.
Nutritional interventions, including calorie restriction,
vitamin supplementation, fresh green tea or extract con-
sumption are often utilised to promote weight loss [2,5-7].
Green tea (Camellia sinensis) is one of the most widely
consumed beverages in the world and experimental
studies indicate that the use of green tea extract is useful
for obesity treatment and prevention [6,8,9]. Among the
many polyphenols present in green tea, epigallocatechin-
3-gallate (EGCG) is the most active form. It is suggested
that the action of EGCG occurs in the sympathetic ner-
vous system, specifically by inhibiting the enzyme
catechol-O-methyl transferase, which degrades norepin-
ephrine. Thus, EGCG could exert regulatory functions onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mal studies, we observed a reduction of blood glucose and
insulin after the consumption of green tea [10].
Friedrich et al. [11] showed that the anti-obesity ef-
fects of EGCG can be explained by decreased food di-
gestibility and nutrient absorption, ultimately resulting
in increased post-prandial fat oxidation and reduced in-
corporation of dietary lipids into tissues. In addition,
Li et al. [12] suggested that EGCG protects rats from
free fatty acid (FFA)-induced insulin resistance.
However, few studies have analysed the inflammatory
status of the WAT of HFD-fed mice and the balance of
anti- and pro-inflammatory adipokines (IL-10 and TNF-
α). In this study, we examined the effects of EGCG con-
sumption on the glycemic and lipid profiles, as well as the
expression of TNF-α, adiponectin, IL-10 and NF-κB p65
in the mesenteric WAT of HFD-fed mice.
Materials and methods
Animals and treatment
The research committee of Universidade Federal de São
Paulo approved all procedures in this study (protocol n°
2009/1796). Three weeks old male Swiss mice were pur-
chased from Centro de Desenvolvimento de Modelos
Experimentais para Medicina e Biologia, and kept under
controlled conditions of light (12 h light–dark cycle with
lights on at 6 am) and temperature (22 ± 1°C). After one
week of acclimation, mice were distributed in four
groups: 1) NS: normolipidic diet treatment with saline;
2) NE: normolipidic diet treatment with EGCG; 3) HFS:
high-fat diet treatment with; 4) HFE: high-fat diet treat-
ment with EGCG.
Throughout the experimental period, the animals were
maintained in collective cages and had ad libitum access
to food and water. The diets were prepared according toTable 1 Macronutrients and micronutrients composition of th
Nutrients Normolip
Carbohydrates (g) 720.7
Carbohydrates (kcal) 75.8%
Protein (g) 140
Protein (kcal) 14.7%
Lipids (g) 40*
Lipids (kcal) 9.5%
Fiber (g) 50
Vitamin mix (g) 10
Mineral mix (g) 35
L-Cysteine (g) 1.8
Choline bitartrate (g) 2.5
Tert-butylhydroquinone (mg) 14
Energy value 3.8 kcal/g
*40 g soybean oil; **312 g lard plus 40 g soybean oil.the recommendations of the American Institute of Nu-
trition. The normolipidic groups and the high-fat groups
were fed with formulation of the AIN-93G diet for rapid
growth [13] (Table 1). A green tea extract, TEAVIGO®
(DSM Nutritional Products, Swiss), containing >90% of
EGCG (50 mg/kg body weight per day) or saline was
administered daily through gavage. Two experimental
groups were conducted, one for 30 and another for
60 days.
Oral Glucose Tolerance Test (OGTT)
In both experiments (30 or 60 days) all animals were
given 12 hours of fast. Initially, the baseline blood was
collected to assess basal glucose concentration from the
tail vein. Then a glucose solution (1.4 g/kg of body
weight) was administrated by gavage. Blood samples
were collected again after 15, 30, 45, 60 and 120 minutes
to obtain the glycemic curve.
Sample collection
At the end of each experiment (30 or 60 days), mice
were euthanized by decapitation without sedation. Blood
was collected and the serum fraction was extracted and
stored at −80°C for further analysis. The adipose tissue
depots: RET, MES and EPI, were dissected, weighed, im-
mediately frozen in liquid nitrogen and stored at −80°C.
Lipid profile measurements
Labtest® commercial kits were used to assess serum total
cholesterol (TC), HDL-cholesterol and triacylglycerol (TG).
The samples were analysed using an enzymatic method.
Analysis of TNF-α, Adiponectin and IL-10 levels
Adipose tissue samples were carefully rinsed in ice-cold
0.9% NaCl to remove any blood contaminants, snape normolipidic and high-fat diet AIN-93G (g/kg diet)
idic diet (g/kg) High fat diet (g/kg)
408.7
30.5%
140
10.5%
352**
59%
50
10
35
1.8
2.5
14
5.36 kcal/g
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tissue (0.1 g – 0.3 g) was homogenized in RIPA buffer
(0.625% Nonidet P-40, 0.625% sodium deoxycholate,
6.25 mM sodium phosphate and 1 mM ethylenediamine
tetraacetic acid at pH 7.4) containing 10 mg/ml protease
inhibitor cocktail (Sigma–Aldrich, St. Louis, Missouri).
Homogenates were centrifuged at 12,000 g for 10 min at
4°C. The supernatant was saved and protein concen-
tration was determined by the Bradford assay (Bio-Rad,
Hercules, CA) using bovine serum albumin (BSA) as a
standard.
Quantitative assessment of TNF-α, adiponectin and
IL-10 levels in adipose tissue was done with ELISA
(DuoSet ELISA, R & D Systems, Minneapolis, MN). The
TNF-α, adiponectin and IL-10 assay sensitivity was
found to be 5.0 pg/ml in the range of 31.2 - 2000 pg/ml.
The intra- and inter-assay variability of the TNF-α, adi-
ponectin and IL-10 kits were, respectively, 2.2-4.8%, 3.4-
6.7% and 4.9-9.5%. The intra-assay variability of the
TNF-α, adiponectin and IL-10 kit was 2.0–4.2%, and its
inter-assay variability was of 3.3 -6.4%. All samples were
run as duplicates, and the mean value was reported.
Protein analysis by western blotting
After euthanasia, the MES was dissected and homoge-
nized in 1.0 mL of solubilization buffer at 4°C [1% Tri-
ton X-100, 100 mm Tris–HCl (pH 7.4), 100 mm sodium
pyrophosphate, 100 mm sodium fluoride, 10 mm EDTA,
10 mm sodium orthovanadate, 2.0 mm phenylmethylsul-
fonyl fluoride (PMSF), and 0.1 mg aprotinin/mL] with a
Polytron (model 713 T; Fisatom Equipamentos Científi-
cos, São Paulo, SP/Brazil). Insoluble material was re-
moved by centrifugation for 30 min at 9,000 × g in a 70.
Ti rotor (Beckman, Fullerton, CA, USA) at 4°C. The
protein concentration of the supernatants was per-
formed by the BCA assay (Bio-Rad, Hercules, CA, USA).
Proteins were denatured by boiling (5 min) in a Laemmli
sample buffer 10 containing 100 mM DTT, run on 8, 10
or 12% SDS-PAGE in a Bio-Rad miniature slab gel
apparatus.
The electrotransfer of proteins from gels to nitrocellu-
lose membranes was performed for ~1.30 h/4gels at
15 V (constant) in a Bio-Rad semi-dry transfer appar-
atus. Nonspecific protein binding to the nitrocellulose
was reduced by preincubation for 2 h at 22°C in block-
ing buffer (5% nonfat dry milk, 10 mM Tris, 150 mM
NaCl and 0.02% Tween 20). The nitrocellulose mem-
branes were incubated overnight at 4°C with antibodies
against NFκBp65 and alpha-tubulin obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), diluted in
1:1000 with blocking buffer supplemented with 1% BSA
and then washed for 30 min in blocking buffer without
BSA. The blots were subsequently incubated with
peroxidase-conjugated secondary antibody for 1 h at22°C. For evaluation of protein loading, membranes
were stripped and reblotted with an anti-alpha-tubulin
antibody as appropriate. Specific bands were detected
by chemiluminescence and visualization/capture was
performed by exposure of the membranes to RX films.
B and intensities were quantified by optical densitometry
of developed autoradiographs (Scion Image software-
Scion Corporation, Frederick, Md., USA).
Statistical analysis
All results are presented as means ± standard error of
the mean (SEM). Statistical significances were assessed
using two-way analysis of variance (ANOVA) followed
by Tukey test as a post hoc analysis to identify signifi-
cant differences among the groups. Differences were
considered significant when p < 0.05.
Results
Body mass and tissue weight
Significant differences in body mass and tissue weight
were found only in the 60-day treatment groups. Differ-
ences in the delta weight (g) were observed between the
HFS and NS groups (p < 0.0001), the HFE and NE
groups (p = 0.042) and the HFS group (p = 0.0036).
The relative weight of the EPI in the HFS group was
significantly higher than the NS group (p < 0.0001) and
the HFE group was significantly higher than the HFS
group (p = 0.0098).
The relative weights of RET, MES and SAT were
higher in the HFS group compared to the NS and HFE
groups and the HFE was higher than the NE group (p ≤
0.02) (Table 2).
Biochemical and hormonal serum analyses
During the 30-day treatment period, only the TC values
differ between the groups, in the HFS group were lower
than in the NS group (p =0.016), and the HFE group
had a higher concentration compared to the HFS group
(p < 0.001).
On the other hand, during the 60-day treatment
period, we observed that TG in the HFE group was sig-
nificantly lower than in the NE group (p = 0.047). There
were no differences in TC between groups. HDL levels
were lower in the HFS group compared to the NS group
(p = 0.0031) and higher in the HFE group compared to
the HFS group (p = 0.0012). There was a significant de-
crease in serum levels of insulin in the HFE group com-
pared to the HFS group (p = 0.022).
We observed that adiponectin in the NS group in-
creased in comparison to the NE (p = 0.008) and HFS
groups (p < 0.0001) and that adiponectin in the HFE group
decreased in comparison to the NE group (p = 0.009). In
addition, the adiponectin/SAT ratio was lower in the HFS
group comparison to the NS group (p = 0.001) and higher
Table 2 Body and adipose tissue weights during two treatment periods (30 days or 60 days) in the experimental
groups
Parameters 30 days of treatment (n = 5-7 per group) 60 days of treatment (n = 11-13 per group)
N S NE HFS HFE N S NE HFS HFE
Initial weight (g) 31.7 ± 0.8 32.9 ± 1.1 31.5 ± 0.8 29.8 ± 1.1 26.7 ± 0.8 26.4 ± 0.5 28.9 ± 0.8 24.7 ± 1.0
Final weight (g) 37.8 ± 3.1 34.8 ± 5.7 36.7 ± 5.6 37.7 ± 6.0 32.7 ± 1.0 31.4 ± 0.8 42.5 ± 1.2* 33.8 ± 1.8$
Delta weight (g) 6.2 ± 1.3 3.3 ± 1.4 5.8 ± 1.3 8.6 ± 1.4 6.1 ± 0.8 5.0 ± 0.8 13.7 ± 1.5* 9.1 ± 1.0**$
EPI (g) 1.49 ± 0.2 1.15 ± 0.2 1.52 ± 0.2 1.67 ± 0.3 0.8 ± 0.1 0.7 ± 0.1 2.0 ± 0.2* 1.0 ± 0.2$
EPI (%) 3.80 ± 0.7 3.11 ± 0.7 3.82 ± 0.7 4.05 ± 0.9 2.5 ± 0.3 2.2 ± 0.2 4.6 ± 0.4* 3.2 ± 0.3$
RET (g) 0.38 ± 0.1 0.35 ± 0.1 0.47 ± 0.1 0.43 ± 0.1 0.3 ± 0.04 0.2 ± 0.02 0.6 ± 0.1* 0.4 ± 0.1$
RET (%) 0.96 ± 0.2 0.98 ± 0.2 1.19 ± 0.2 1.07 ± 0.2 0.8 ± 0.1 0.6 ± 0.1 1.4 ± 0.1* 1.1 ± 0.1**$
MES (g) 0.55 ± 0.1 0.51 ± 0.1 0.60 ± 0.1 0.68 ± 0.1 0.3 ± 0.05 0.2 ± 0.03 0.8 ± 0.1* 0.4 ± 0.1$
MES (%) 1.39 ± 0.2 1.42 ± 0.3 1.51 ± 0.2 1.67 ± 0.3 0.8 ± 0.1 0.8 ± 0.1 1.9 ± 0.2* 1.4 ± 0.2**$
SAT (g) 2.41 ± 0.3 2.02 ± 0.3 2.60 ± 0.3 2.78 ± 0.5 1.3 ± 0.2 1.1 ± 0.1 3.5 ± 0.3* 1.8 ± 0.2$
SAT (%) 6.16 ± 0.7 5.51 ± 0.5 6.53 ± 0.6 6.79 ± 0.9 3.2 ± 0.6 3.6 ± 0.3 7.4 ± 0.8* 4.4 ± 0.7**$
Data are mean ± SEM. *Different from NS. **Different from NE. $Different from HFS.
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0.009) (Table 3).
Cytokines in mesenteric adipose tissue
In both treatment periods (30 or 60 days), no differences
were observed in mesenteric cytokines levels between
any of the groups (data not shown).
OGTT
Glucose tolerance, as measured by OGTT, did not differ
between any of the groups in the 30-day treatment
period. However, in the 60-day treatment groups, we ob-
served differences between the HFS group and the NS
group (p = 0.003) as well as between the HFE group and
the NE group (p = 0.001) (Figure 1).
Quantification of inflammatory proteins
Western blot analysis shows that there were no differ-
ences in NF-kBp65 protein levels between any of the
groups treated for 30 days.Table 3 Triacylglycerol (TG), Total Cholesterol (TC), High Densi
adiponectin /sum of adipose tissue (SAT) concentrations during
experimental groups
Parameters 30 Days of Treatment (n = 5-7 per group)
N S NE HFS HF
TG (mg/dL) 169.8 ± 19.1 166.8 ± 9.9 152.0 ± 8.5 137
TC (mg/dL) 174.7 ± 7.5 176.5 ± 5.0 155.7 ± 7.5* 181
HDL-C (mg/dL) 36.21 ± 2.2 40.99 ± 4.8 39.32 ± 4.5 36.
Insulin (ng/mL) 0.6 ± 0.1 0.5 ± 0.1 0.3 ± 0.04 0.4
Adiponectin (μg/mL) - - - -
Adiponectin/SAT - - - -
Data are mean ± SEM (n = 5-8 per group); *Different from NS. **Different from NE. $However, NF-kB p65 expression in the MES was in-
creased in the NE group compared to the other groups
after the 60-day treatment period (p < 0.005) (Figure 2).
Discussion
The pathogenesis of obesity and metabolic diseases is as-
sociated with intake of a high-fat diet. Chronic systemic
inflammation directly contributes to the development of
obesity [14]. Therefore, suppressing chronic inflamma-
tion may be a good strategy to prevent and/or treat
obesity. Interestingly, previous studies suggest that the
positive impacts of polyphenols could work through their
ability to suppress chronic inflammation [15,16]. Based on
this knowledge, an alternative strategy, such as phytother-
apy treatment, may benefit modern obesity therapies.
In this experimental study, we attempted to induce
metabolic changes in mice by administration of a high-
fat diet and then compared the outcomes of treatment
with EGCG or saline over either 30-day or 60-day pe-
riods. Our results show that the treatment of Swiss mice
with a high-fat diet for 30 days did not increase weightty Lipoprotein - Cholesterol (HDL- C), insulin, adiponectin,
two treatment periods (30 days our 60 days) in the
60 Days of Treatment (n = 11-13 per group)
E N S NE HFS HFE
.6 ± 5.3 174.0 ± 16.1 184.0 ± 14.4 145.1 ± 5.4 136.6 ± 5.4**
.6 ± 6.5$ 176.7 ± 6.4 212.0 ± 11.4 194.9 ± 13.6 178.1 ± 8.6
89 ± 1.9 42.1 ± 1.3 44.4 ± 0.8 37.0 ± 1.0* 42.6 ± 1.7$
± 0.05 1.2 ± 0.2 1.0 ± 0.3 1.9 ± 0.2 0.8 ± 0.1$
3.4 ± 0.2 2.5 ± 0.2* 1.8 ± 0.2* 1.6 ± 0.1**
99.8 ± 14.8 91.6 ± 8.6 30.1 ± 5.4* 33.9 ± 5.2$
Different from HFS.
Figure 1 Oral Glucose Tolerance Test (OGTT) during two treatment periods (30 days our 60 days) in the experimental groups.
*Different from NS (p = 0.003); ** different from HFE (p = 0.001).
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in OGTT or inflammatory profile. The experimental
period of 30 days may be too short to show significant
changes in these parameters.
On the other hand, we demonstrated that a 60-day
treatment period of high-fat diet and EGCG treatment
was effective in triggering inflammatory processes such
as a decrease in adiponectin and induced changes in glu-
cose homeostasis, weight mass, TG and HDL-C.
The anti-obesity effects of green tea are most likely due
to its capacity to elevate thermogenesis and fat oxidationFigure 2 Quantification of NF-kB p65 protein levels during the two tr
groups. *Different from NS compared to the others groups (p = 0.005).[17]. Thus, we hypothesised that EGCG treatment reduces
body-fat mass by changes in cytokine production and
pro-inflammatory molecule protein levels. Our study is
in agreement with other reports in the literature that
clinical studies have shown that the consumption of
EGCG is connected with weight loss [18].
Our results contrast with those currently expected once
the literature evidences the increase in adiponectin with
weight loss [19]. However, some studies also showed no in-
crease in adiponectin with weight loss but still found an im-
provement in insulin resistance, agreeing with the findingseatment periods (30 days our 60 days) in the experimental
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to increased insulin sensitivity in other ways independent of
the action of adiponectin, such as mobilisation of intracellu-
lar lipid content of the liver [22].
When we analysed serum adiponectin levels we ob-
served that the high-fat diet was effective in reducing
serum adiponectin levels and that EGCG contributed to
the decrease in both, normolipidic as in high-fat diet.
However, when we need to consider the amount of fat in
each mouse and adjust the serum adiponectin level with
the SAT, the results showed that EGCG improved the
adiponectin concentration.
In another study, green tea extract added to the diet
(1%) did not alter the concentrations of adiponectin [23]
in adult mice fed a high-fat diet for 12 weeks. Addition
of 1.2% green tea extract into the water decreased adipo-
nectin concentrations in mice after eight weeks of treat-
ment; however [24]. By adjusting our results for
adiponectin/STA we observed that the negative effect of
green tea disappears. The change in adiponectin could
be explained by the reduced fat mass in the HFS and
HFE groups since this is a cytokine that is produced by
adipocytes.
EGCG treatment caused decreased adipose tissue de-
posits corresponding to the improvement of insulin
levels in the HFE group. Several studies have shown that
weight loss is associated with decreased insulin resist-
ance and inflammatory markers [25]. These findings
demonstrate that EGCG may be a novel, plant-derived
compound capable of reducing the risk of HFD-induced
glucose intolerance.
Fu et al. [26] examined the potential (−)-epigallocate-
chin gallate (EGCG, 0.05% in drinking water) on effect-
ively delaying the onset of type 1 diabetes (T1D) in non-
obese diabetic (NOD) mice. Mice supplemented with
EGCG had significantly higher plasma insulin levels and
survival rates compared with the control animals. EGCG
had no significant effects on food or water intake or body
weight in mice, suggesting that the glucose-lowering effect
was not due to an alteration in these parameters. While
EGCG did not modulate insulinemia, it did elevate the
levels of the circulating anti-inflammatory cytokine IL-10
in NOD mice. These findings demonstrate that EGCG
may be a novel, plant-derived compound capable of redu-
cing the risk of T1D.
Obesity and insulin resistance are associated with low
grade chronic systemic inflammation [27]. In the present
study, we observed no changes in the cytokine profile
during either treatment period (30 days or 60 days).
However, we did observe differences in delta weight,
relative RET, MES, EPI and SAT weights, adiponectin
levels and glucose homeostasis. We hypothesise that
these differences will become more pronounced in a
longer trial period (>60 days).We see the normocaloric diet with EGCG increased
phosphorylation of the p65 subunit from the NF-kB
complex in MES. These are unexpected effects of the
administration of EGCG. Perhaps the consumption of
antioxidants from the EGCG caused an adverse effect on
the NE group.
In summary, our data demonstrated that the adminis-
tration of EGCG (60 days) promoted a significant im-
provement in glucose tolerance, decreased adipose tissue
deposits, weight mass, TG and HDL-C only when asso-
ciated with high-fat diet treatment. More studies are re-
quired to better understand the mechanism of this effect
and to further elucidate the role of EGCG in reversing
the inflammatory effects triggered by a high-fat diet.
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